Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

NOVARTIS, INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
dff31ce9-ad36-4ed6-9b6e-6c244997cb7d
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.

Literal federal measure citations: H.R.5376

MMM · Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.

Literal federal measure citations: H.R.1672, S.3131, H.R.5539, S.832, H.R.1492

TRD · Trade (domestic/foreign)

Tariffs.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.